Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin

Xenobiotica

Volumn 40, Issue 12, 2010, Pages 807-816

  Babbar, Sunita ^a   Chanda, Sanjay ^b   Bley, Keith ^a  

^a NeurogesX Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

chili peppers; hepatocytes; Liver microsomes; pain

Indexed keywords

CAPSAICIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LIVER CELL CULTURE; LIVER MICROSOME; MALE; PEPPER; SCHOOL CHILD;

CAPSAICIN; CELLS, CULTURED; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ASSAYS; ENZYME INDUCTION; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED;

CAPSICUM FRUTESCENS;

EID: 78249268846     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.520044     Document Type: Article

References (46)

1. Alawi K, Keeble J. (2010). Te paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ter 125:181-195.
2. Anandakumar P, Jagan S, Kamaraj S, Ramakrishnan G, Clara JB, Pathitha D, Kavitha T, Devaki T. (2009). Ameliorating effect of capsaicin on alterations in lipid metabolism during mice lung carcinoma. Arch Pharm Res 32:229-234.
3. Babbar S, Marier JF, Mouksassi MS, Beliveau M, Vanhove GF, Chanda S, Bley K. (2009). Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ter Drug Monit 31:502-510.
4. Bachmann KA, Lewis JD, Fuller MA, Bonfiglio MF. (2004). Lexi-Comp's Drug Interactions Handbook Lexi-Comp; 2 edition.
5. Blumenthal M, Busse W, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS. (1998) The Complete German Commission E Monographs. Austin, TX: American Botanical Council: Integrative Medicine Communications.
6. Burke MD, Mayer RT. (1974). Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 2:583-588.
7. Chaiyasit K, Khovidhunkit W, Wittayalertpanya S. (2009). Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Tai 92:108-113.
8. Chanda S, Bashir M, Babbar S, Koganti A, Bley K. (2008). In vitro hepatic and skin metabolism of capsaicin. Drug Metab Dispos 36:670-675.
9. Dairam A, Fogel R, Daya S, Limson JL. (2008). Antioxidant and ironbinding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. J Agric Food Chem 56:3350-3356.
10. Dutton DR, Parkinson A. (1989). Reduction of 7-alkoxyresorufins by NADPH-cytochrome P450 reductase and its differential effects on their O-dealkylation by rat liver microsomal cytochrome P450. Arch Biochem Biophys 268:617-629.
11. EC Scientific Committee on Food. (2002). Opinion of the Scientific Community on Food on Capsaicin. http://ec.europa.eu/food/fs/sc/scf/out120-en. pdf.
12. EMEA. (1997). Note for guidance on the investigation of drug interactions. http://www.emea.europa.eu/pdfs/human/ewp/056095en.pdf
13. EMEA. (2009). EPARs for authorised medicinal products for human use: Qutenza. http://www.emea.europa.eu/humandocs/Humans/EPAR/qutenza/qutenza.htm.
14. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
15. Foti RS, Wahlstrom JL. (2008). Prediction of CYP-mediated drug interactions in vivo using in vitro data. IDrugs 11:900-905.
16. Gannett PM, Iversen P, Lawson T. (1990). Te mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin. Bioorg Chem 18:185-198
17. Gómez-Lechón MJ, Donato T, Ponsoda X, Castell JV. (2003). Human hepatic cell cultures: in vitro and in vivo drug metabolism. Altern Lab Anim 31:257-265.
18. Huang SP, Chen JC, Wu CC, Chen CT, Tang NY, Ho YT, Lo C, Lin JP, Chung JG, Lin JG. (2009). Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res 29:165-174.
19. Hutzler JM, Tracy TS. (2002). Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
20. Knotkova H, Pappagallo M, Szallasi A. (2008). Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain 24:142-154.
21. Leemann T, Transon C, Dayer P. (1993). Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci 52:29-34.
22. Lu AY, Levin W. (1972). Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. Biochem Biophys Res Commun 46:1334-1339.
23. Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. (2002). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Drug-Drug Interactions (Rodrigues AD, ed.) Marcel Dekker, Inc., New York, NY.
24. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431.
25. Meier UT, Dayer P, Malè PJ, Kronbach T, Meyer UA. (1985). Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ter 38:488-494.
26. Miller CH, Zhang Z, Hamilton SM, Teel RW. (1993). Effects of capsaicin on liver microsomal metabolism of the tobacco-specific nitrosamine NNK. Cancer Lett 75:45-52.
27. Miller MS, Brendel K, Burks T F, Sipes IG. (1983). Interaction of capsaicinoids with drug-metabolizing systems. Relationship to toxicity. Biochem Pharmacol 32:547-551.
28. Mudra DR, Parkinson A. (2001). Preparation of Hepatocytes; Unit 14.2. In: Current Protocols in Toxicology, Volume 1 (Maines M. D. ed.), John Wiley and Sons, Inc., New York, New York.
29. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
30. nd ed. (Rodrigues AD, ed.) pp 231-358, Informa Healthcare, New York.
31. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. (1990). Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573.
32. Reilly CA, Ehlhardt WJ, Jackson DA, Kulanthaivel P, Mutlib AE, Espina RJ, Moody DE, Crouch DJ, Yost GS. (2003). Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol 16:336-349.
33. Reilly CA, Yost GS. (2006). Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes. Drug Metab Rev 38:685-706.
34. Robertson P, De Cory HH, Madan A, Parkinson A. (2000). In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 28:664-671.
35. Singh SS. (2006). Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 7:165-182.
36. Sonderfan AJ, Parkinson A. (1988). Inhibition of steroid 5 alphareductase and its effects on testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 265:208-218.
37. Surh YJ, Lee SS. (1995). Capsaicin, a double-edged sword: toxicity, metabolism, and chemopreventive potential. Life Sci 56:1845-1855.
38. Surh YJ, Lee RC, Park KK, Mayne ST, Liem A, Miller JA. (1995). Chemoprotective effects of capsaicin and diallyl sulfide against mutagenesis or tumorigenesis by vinyl carbamate and N-nitrosodimethylamine. Carcinogenesis 16:2467-2471.
39. Surh YJ, Lee SS. (1996). Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Food Chem Toxicol 34:313-316.
40. Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 18:1071-1080.
41. Turgut C, Newby BM, Cutright TJ. (2004). Determination of optimal water solubility of capsaicin for its usage as a non-toxic antifoulant. Environ Sci Pollut Res Int 11:7-10.
42. US FDA: Guidance for Industry. (2006). In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling.
43. US FDA: Drugs@FDA. (2009). FDA Approved Drug Products. QUTENZA Drug Details.
44. Wood AW, Ryan DE, Tomas PE, Levin W. (1983). Regio-and stereoselective metabolism of two C19 steroids by five highly purified and reconstituted rat hepatic cytochrome P-450 isozymes. J Biol Chem 258:8839-8847.
45. Zhang R, Humphreys I, Sahu RP, Shi Y, Srivastava SK. (2008). In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis 13:1465-1478.
46. Zhang Z, Hamilton SM, Stewart C, Strother A, Teel RW. (1993). Inhibition of liver microsomal cytochrome P450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res 13:2341-2346.